Literature DB >> 29378722

Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis.

Nicholas S Britt1, David J Ritchie2,3, Marin H Kollef4, C A Burnham5,6,7, Michael J Durkin8, Nicholas B Hampton9, Scott T Micek2,3.   

Abstract

In a retrospective analysis of 215 patients with carbapenem-resistant Pseudomonas aeruginosa sepsis, we observed a significantly higher risk of mortality associated with respiratory tract infection (risk ratio [RR], 1.20; 95% confidence interval [CI], 1.04 to 1.39; P = 0.010) and lower risk with urinary tract infection (RR, 0.80; 95% CI, 0.71 to 0.90; P = 0.004). Aminoglycoside monotherapy was associated with increased mortality, even after adjusting for confounders (adjusted RR, 1.72; 95% CI, 1.03 to 2.85; P = 0.037), consistent across multiple sites of infection.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; carbapenem resistance; multidrug resistance; sepsis

Mesh:

Substances:

Year:  2018        PMID: 29378722      PMCID: PMC5913923          DOI: 10.1128/AAC.02400-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.

Authors:  Julie M Varghese; Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care Clin       Date:  2011-01       Impact factor: 3.598

Review 2.  Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.

Authors:  Yangmin Hu; Leiqing Li; Wenlu Li; Huimin Xu; Ping He; Xiaofeng Yan; Haibin Dai
Journal:  Int J Antimicrob Agents       Date:  2013-10-01       Impact factor: 5.283

Review 3.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

4.  Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.

Authors:  Deanna J Buehrle; Ryan K Shields; Lloyd G Clarke; Brian A Potoski; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

Review 6.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

7.  Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis.

Authors:  Qianqian Liu; Xiaoqing Li; Wenzhang Li; Xinmiao Du; Jian-Qing He; Chuanmin Tao; Yulin Feng
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

Review 8.  Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.

Authors:  Yu Zhang; Xiao-Li Chen; Ai-Wei Huang; Su-Ling Liu; Wei-Jiang Liu; Ni Zhang; Xu-Zai Lu
Journal:  Emerg Microbes Infect       Date:  2016-03-23       Impact factor: 7.163

9.  Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Bin Cai; Roger Echols; Glenn Magee; Juan Camilo Arjona Ferreira; Gareth Morgan; Mari Ariyasu; Takuko Sawada; Tsutae Den Nagata
Journal:  Open Forum Infect Dis       Date:  2017-08-16       Impact factor: 3.835

  9 in total
  6 in total

1.  Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model.

Authors:  Aaron J Heffernan; Fekade B Sime; Derek S Sarovich; Michael Neely; Yarmarly Guerra-Valero; Saiyuri Naicker; Kyra Cottrell; Patrick Harris; Katherine T Andrews; David Ellwood; Steven C Wallis; Jeffrey Lipman; Keith Grimwood; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

2.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

3.  The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections.

Authors:  Linli Lu; Cong Xu; Yishu Tang; Liwen Wang; Qian Cheng; Xin Chen; Jian Zhang; Ying Li; Han Xiao; Xin Li
Journal:  Infect Drug Resist       Date:  2022-06-04       Impact factor: 4.177

4.  Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales.

Authors:  Jessica R Howard-Anderson; Michelle Earley; Lauren Komarow; Lilian Abbo; Deverick J Anderson; Jason C Gallagher; Matthew Grant; Angela Kim; Robert A Bonomo; David van Duin; L Silvia Muñoz-Price; Jesse T Jacob
Journal:  Infect Control Hosp Epidemiol       Date:  2022-02-02       Impact factor: 6.520

5.  Continuous high-dose infusion of doripenem in a pneumonia patient infected by carbapenem-resistant Pseudomonas aeruginosa: a case report.

Authors:  Kazutaka Oda; Hidenobu Kamohara; Tomomi Katanoda; Yumi Hashiguchi; Koji Iwamura; Kisato Nosaka; Hirofumi Jono; Hideyuki Saito
Journal:  J Pharm Health Care Sci       Date:  2019-07-08

6.  Insights into the Clinical Management of Carbapenem-Resistant Gram-Negative Infections: An Italian Retrospective Clinical Chart Review

Authors:  Guido Granata; Davide Manissero; Maria Vittoria Oppia; Keiko Tone; Bin Cai; Christopher Longshaw; Carolina Venditti; Nicola Petrosillo
Journal:  Infect Dis Rep       Date:  2020-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.